These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 26833348

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T, Lin M, Li W, Fan X, Du T, Zhao Y, Zhang X.
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
    Kvapil M.
    Vnitr Lek; 2013 Sep; 59(9):800-6. PubMed ID: 24073952
    [Abstract] [Full Text] [Related]

  • 27. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
    Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E.
    Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial.
    Lundby-Christensen L, Vaag A, Tarnow L, Almdal TP, Lund SS, Wetterslev J, Gluud C, Boesgaard TW, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, Røder M, Mathiesen ER, Jensen T, Vestergaard H, Hedetoft C, Breum L, Duun E, Sneppen SB, Pedersen O, Hemmingsen B, Carstensen B, Madsbad S.
    BMJ Open; 2016 Feb 25; 6(2):e008377. PubMed ID: 26916685
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P.
    Diabetes Care; 2006 Jun 25; 29(6):1269-74. PubMed ID: 16732007
    [Abstract] [Full Text] [Related]

  • 34. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
    Yki-Järvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, Riddle MC, EDITION 2 Study Investigators.
    Diabetes Care; 2014 Dec 25; 37(12):3235-43. PubMed ID: 25193531
    [Abstract] [Full Text] [Related]

  • 35. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
    Garber AJ, Clauson P, Pedersen CB, Kølendorf K.
    J Am Geriatr Soc; 2007 Nov 25; 55(11):1735-40. PubMed ID: 17979896
    [Abstract] [Full Text] [Related]

  • 36. Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE).
    Karnieli E, Baeres FM, Dzida G, Ji Q, Ligthelm R, Ross S, Svendsen AL, Yale JF, SOLVE Study Group.
    Drugs Aging; 2013 Mar 25; 30(3):167-75. PubMed ID: 23371395
    [Abstract] [Full Text] [Related]

  • 37. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ.
    Diabetes Obes Metab; 2007 May 25; 9(3):418-27. PubMed ID: 17391170
    [Abstract] [Full Text] [Related]

  • 38. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May 25; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 39. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J.
    JAMA; 2017 Oct 17; 318(15):1460-1470. PubMed ID: 29049653
    [Abstract] [Full Text] [Related]

  • 40. A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.
    Abreu M, Tumyan A, Elhassan A, Peicher K, Papacostea O, Dimachkie P, Siddiqui MS, Pop LM, Gunasekaran U, Meneghini LF, Adams-Huet B, Li X, Lingvay I.
    Diabetes Obes Metab; 2019 Sep 17; 21(9):2133-2141. PubMed ID: 31144435
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.